Skip to main content
Article

Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis

Chia-Hung LinDepartment of Radiology, H. Mondor Hospital, AP-HP/Paris 12 University, Créteil, FranceEmmanuel IttiDepartment of Nuclear Medicine,Corinne HaïounH. Mondor Hospital , AP-HP/Paris 12 University , Cr éteil , France;Yolande PetegniefHôpitaux Universitaires Henri-MondorAlain LucianiDepartment of Radiology , H. Mondor Hospital , AP-HP/Paris 12 University , Cr éteil , France;Jehan DupuisDepartment of Hematology, H. Mondor Hospital, AP-HP/ParisGaetano PaoneUniversity , Paris , FranceJean‐Noël TalbotDepartment of Nuclear Medicine, Tenon Hospital, AP-HP/ParisAlain RahmouniService de M édecine Nucl éaire , H ôpital Henri Mondor , 51 Ave. du Marechal de Lattre de Tassigny , 94010 Cr éteil , FranceM. MeignanDepartment of Nuclear Medicine ,
2007en
ABI

Abstract

UNLABELLED: The purpose of this study was to assess the prognostic value of early (18)F-FDG PET using standardized uptake value (SUV) compared with visual analysis in patients with diffuse large B-cell lymphoma (DLBCL). METHODS: Ninety-two patients with newly diagnosed DLBCL underwent (18)F-FDG PET prospectively before and after 2 cycles of chemotherapy (at midtherapy). Maximum SUV (SUVmax) and mean SUV (SUVmean) normalized to body weight and body surface area, as well as tumor-to-normal ratios, were computed on the most intense uptake areas. The SUVs, tumor-to-normal ratios, and their changes over time were compared with visual analysis for predicting event-free survival (EFS) and overall survival, using receiver-operating-characteristic (ROC) analysis. Survival curves were estimated with Kaplan-Meier analysis and compared using the log-rank test. RESULTS: With visual analysis, the accuracy of early PET to predict EFS was 65.2%. The 2-y estimate for EFS was 51% (95% confidence interval [CI], 34%-68%) in the PET-positive group compared with 79% (95% CI, 68%-90%) in the PET-negative group (P = 0.009). An optimal cutoff value of 65.7% SUVmax reduction from baseline to midtherapy obtained from ROC analysis yielded an accuracy of 76.1% to predict EFS. The 2-y estimate for EFS was 21% (95% CI, 0%-42%) in patients with SUVmax reduction 65.7% (P < 0.0001). Fourteen patients considered as positive on visual analysis could have been reclassified as good responders. CONCLUSION: SUV-based assessment of therapeutic response during first-line chemotherapy improves the prognostic value of early (18)F-FDG PET compared with visual analysis in DLBCL.

Identifiers

Citations and references

Cited by 038 references